Eltrombopag Olamine Patent Expiration
Eltrombopag Olamine is used for increasing platelet counts in patients with chronic immune thrombocytopenia and chronic hepatitis C to facilitate interferon-based therapy. It was first introduced by Novartis Pharmaceuticals Corp
Eltrombopag Olamine Patents
Given below is the list of patents protecting Eltrombopag Olamine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Promacta | US6280959 | Metal complexes |
Oct 30, 2018
(Expired) | Novartis |
| Promacta |
US6280959 (Pediatric) | Metal complexes |
Apr 30, 2019
(Expired) | Novartis |
| Promacta | US7160870 | Thrombopoietin mimetics |
Nov 20, 2022
(Expired) | Novartis |
| Promacta |
US7160870 (Pediatric) | Thrombopoietin mimetics |
May 20, 2023
(Expired) | Novartis |
| Promacta | US7332481 | Thrombopoietin mimetics |
May 24, 2021
(Expired) | Novartis |
| Promacta |
US7332481 (Pediatric) | Thrombopoietin mimetics |
Nov 24, 2021
(Expired) | Novartis |
| Promacta | US7452874 | Thrombopoietin mimetics |
May 24, 2021
(Expired) | Novartis |
| Promacta |
US7452874 (Pediatric) | Thrombopoietin mimetics |
Nov 24, 2021
(Expired) | Novartis |
| Promacta | US7473686 | Thrombopoietin mimetics |
May 24, 2021
(Expired) | Novartis |
| Promacta |
US7473686 (Pediatric) | Thrombopoietin mimetics |
Nov 24, 2021
(Expired) | Novartis |
| Promacta | US7547719 | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) | Jul 13, 2025 | Novartis |
| Promacta |
US7547719 (Pediatric) | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) | Jan 13, 2026 | Novartis |
| Promacta | US7790704 | Thrombopoietin mimetics |
May 24, 2021
(Expired) | Novartis |
| Promacta |
US7790704 (Pediatric) | Thrombopoietin mimetics |
Nov 24, 2021
(Expired) | Novartis |
| Promacta | US7795293 | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
May 21, 2023
(Expired) | Novartis |
| Promacta |
US7795293 (Pediatric) | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Nov 21, 2023
(Expired) | Novartis |
| Promacta | US8052993 | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) | Aug 01, 2027 | Novartis |
| Promacta |
US8052993 (Pediatric) | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) | Feb 01, 2028 | Novartis |
| Promacta | US8052994 | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) | Aug 01, 2027 | Novartis |
| Promacta |
US8052994 (Pediatric) | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) | Feb 01, 2028 | Novartis |
| Promacta | US8052995 | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) | Aug 01, 2027 | Novartis |
| Promacta |
US8052995 (Pediatric) | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) | Feb 01, 2028 | Novartis |
| Promacta | US8062665 | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) | Aug 01, 2027 | Novartis |
| Promacta |
US8062665 (Pediatric) | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) | Feb 01, 2028 | Novartis |
| Promacta | US8071129 | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) | Aug 01, 2027 | Novartis |
| Promacta |
US8071129 (Pediatric) | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) | Feb 01, 2028 | Novartis |
| Promacta | US8828430 | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) | Aug 01, 2027 | Novartis |
| Promacta |
US8828430 (Pediatric) | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) | Feb 01, 2028 | Novartis |
| Promacta Kit | US6280959 | Metal complexes |
Oct 30, 2018
(Expired) | Novartis |
| Promacta Kit |
US6280959 (Pediatric) | Metal complexes |
Apr 30, 2019
(Expired) | Novartis |
| Promacta Kit | US7160870 | Thrombopoietin mimetics |
Nov 20, 2022
(Expired) | Novartis |
| Promacta Kit |
US7160870 (Pediatric) | Thrombopoietin mimetics |
May 20, 2023
(Expired) | Novartis |
| Promacta Kit | US7332481 | Thrombopoietin mimetics |
May 24, 2021
(Expired) | Novartis |
| Promacta Kit |
US7332481 (Pediatric) | Thrombopoietin mimetics |
Nov 24, 2021
(Expired) | Novartis |
| Promacta Kit | US7452874 | Thrombopoietin mimetics |
May 24, 2021
(Expired) | Novartis |
| Promacta Kit |
US7452874 (Pediatric) | Thrombopoietin mimetics |
Nov 24, 2021
(Expired) | Novartis |
| Promacta Kit | US7473686 | Thrombopoietin mimetics |
May 24, 2021
(Expired) | Novartis |
| Promacta Kit |
US7473686 (Pediatric) | Thrombopoietin mimetics |
Nov 24, 2021
(Expired) | Novartis |
| Promacta Kit | US7547719 | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) | Jul 13, 2025 | Novartis |
| Promacta Kit |
US7547719 (Pediatric) | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) | Jan 13, 2026 | Novartis |
| Promacta Kit | US7790704 | Thrombopoietin mimetics |
May 24, 2021
(Expired) | Novartis |
| Promacta Kit |
US7790704 (Pediatric) | Thrombopoietin mimetics |
Nov 24, 2021
(Expired) | Novartis |
| Promacta Kit | US7795293 | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
May 21, 2023
(Expired) | Novartis |
| Promacta Kit |
US7795293 (Pediatric) | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Nov 21, 2023
(Expired) | Novartis |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Eltrombopag Olamine's patents.
Latest Legal Activities on Eltrombopag Olamine's Patents
Given below is the list recent legal activities going on the following patents of Eltrombopag Olamine.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 24 May, 2023 | US8071129 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 10 May, 2023 | US8062665 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 26 Apr, 2023 | US8052994 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 26 Apr, 2023 | US8052995 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 26 Apr, 2023 | US8052993 |
| Expire Patent | 10 Oct, 2022 | US7790704 |
| Maintenance Fee Reminder Mailed | 25 Apr, 2022 | US7790704 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 02 Mar, 2022 | US7795293 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 23 Feb, 2022 | US8828430 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 02 Dec, 2020 | US7547719 |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Eltrombopag Olamine Generics
Several generic applications have been filed for Eltrombopag Olamine.
Given below is the list of companies who have filed for Eltrombopag Olamine generic.
1. ANNORA PHARMA
Annora Pharma Private Ltd has filed for 2 different strengths of generic version for Eltrombopag Olamine. Given below are the details of the strengths of this generic introduced by Annora Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 12.5MG ACID/PACKET | for suspension | Prescription | ORAL | AB | Apr 18, 2024 |
| EQ 25MG ACID/PACKET | for suspension | Prescription | ORAL | AB | Apr 18, 2024 |